July 15, 2019 Press release - Non-regulatory Oslo, Norway, 15 July 2019: Targovax ASA (“Targovax” or “the Company”; OSE: TRVX), a clinical stage biotechnology company developing immune activators to target hard-to-treat solid tumors, announces the start of the expansion part... read more

Paris, France, July 11, 2019, 5.45 pm CEST – GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on discovering and developing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced... read more

11.07.2019 14:32 Oslo, Norway, 11 July 2019 Nordic Nanovector ASA (OSE: NANO) announces that the final patient has been enrolled in the LYMRIT 37-05 clinical trial of Betalutin® (177Lu-satetraxetan-lilotomab) in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) n... read more

Improving all fundamentals Q2 2019 highlights Total net revenues of SEK 201.2 million (199.7), up 0.8 percent and 19.1 percent when excluding ex-US milestone payment of SEK 30.8 million in Q2 2018 Zubsolv® US net revenues of SEK 184.4 million (158.4), up 16.4 percent in SEK and 6.7 percent... read more

July 9, 2019 at 7:00 AM EDT PDF Version Company to receive rights to novel GLP-1/glucagon dual agonist that addresses obesity and metabolic dysfunction, primary causes of NASH Greater impact on liver fat, inflammation and fibrosis compared to leading NASH candidates in established... read more